Announcement PDF ABN 16 165 160 841 +61 (0) 3 9123 1140 | info@ampliatx.com Level 5, 90 William Street, Melbourne VIC 3000 Australia www.ampliatx.com 27 NOVEMBER 2025 ASX RELEASE APPENDIX 4D AND FINANCIAL REPORT HALF YEAR ENDED 30 SEPTEMBER 2025 Melbourne, Australia: Amplia Therapeutics Limited (ASX: ATX; OTCQB: INNMF), referred to as “Amplia” or “the Company,” announces its Appendix 4D and Financial Report for the Half Year ended 30 September 2025. This ASX announcement was approved and authorised for release by the Board of Amplia Therapeutics. Investor Contact: Dr Chris Burns Chief Executive Officer chris@ampliatx.com Investor Contact (US): Robert Giordano GGroup Life Sciences rjgiordano@ggrouplifesciences.com Media Contact: Haley Chartres haley@hck.digital +61 423 139 163 About Amplia Therapeutics Limited Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer and Amplia has a particular development focus in fibrotic cancers such as pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF). For more information visit www.ampliatx.com and follow Amplia on X (@ampliatx) and LinkedIn. About Narmafotinib Narmafotinib (AMP945) is the company’s best-in-class inhibitor of the protein FAK, a protein over-expressed in pancreatic cancer and a drug target gaining increasing attention for its role in solid tumours. The drug, which is a highly potent and selective inhibitor of FAK, has shown promising data in a range of preclinical cancer studies. Narmafotinib is currently undergoing a clinical trial (the ACCENT trial) where it is dosed in combination with the chemotherapies gemcitabine and Abraxane in first-line patients with advanced pancreatic cancer. The trial has already achieved its desired outcome in achieving a confirmed response rate of 33%, superior to 23% reported in the benchmark MPACT study for gemcitabine and Abraxane alone, An interim median PFS of 7.6 months has also been reported. A second trial – AMPLICITY – has recently opened and is being run under an IND at sites in Australia and the US, investigating the combination of narmafotinib with the chemotherapy FOLFIRINOX in advanced pancreatic cancer patients. About the ACCENT Trial The ACCENT trial is entitled ‘A Phase 1b/2a, Multicentre, Open Label Study of the Pharmacokinetics, Safety and Efficacy of AMP945 in Combination with Nab-paclitaxel and Gemcitabine in Pancreatic Cancer Patients’. The trial is a single-arm open label study conducted in two stages. The first stage (Phase 1b), completed in November 2023, determined an optimal dose of narmafotinib (AMP945) by assessing the safety, tolerability, pharmacokinetics and preliminary efficacy when dosed in combination with gemcitabine and Abraxane in first-line patients with advanced pancreatic cancer. The second stage (Phase 2a) of the trial is designed to assess efficacy in combination with gemcitabine and Abraxane.The primary endpoints are ObjectiveResponse Rate (ORR) and safety and tolerability, with secondary endpoints including Progression Free Survival (PFS), Overall Survival (OS) and Duration on Trial (DOT). The trial is being conducted at seven sites in Australia and five sites in South Korea. More information about the ACCENT trial canbefound via the ACCENT trial site, the Amplia Therapeutics website and at ClinicalTrials.gov under the identifier NCT05355298. Amplia Therapeutics Limited Appendix 4D Half-year report 1. Company details Name of entity: Amplia Therapeutics Limited ACN: 165 160 841 Reporting period: For the half-year ended 30 September 2025 Previous period: For the half-year ended 30 September 2024 2. Results for announcement to the market $ Revenues from ordinary activities and other income up 90% to 2,835,097 Loss from ordinary activities after tax attributable to the owners of Amplia Therapeutics Limited up 48% to (4,176,563) Loss for the half-year attributable to the owners of Amplia Therapeutics Limited up 48% to (4,176,563) Dividends The Directors have resolved that no dividend will be paid this half year. Comments The loss for the Group after providing for income tax for the half-year ended 30 September 2025 amounted to $4,176,563 (30 September 2024: $2,814,163). 3. Net tangible assets Reporting period Previous period Cents Cents Net tangible assets per ordinary security 6.8 3.4 4. Control gained over entities Not applicable. 5. Loss of control over entities Not applicable. 6. Dividends Current period There were no dividends paid, recommended or declared during the current financial period. Previous period There were no dividends paid, recommended or declared during the previous financial period. 7. Dividend reinvestment plans Not applicable. Amplia Therapeutics Limited Appendix 4D Half-year report 8. Details of associates and joint venture entities Not applicable. 9. Foreign entities Details of origin of accounting standards used in compiling the report: Not applicable. 10. Audit qualification or review Details of audit/review dispute or qualification (if any): The financial statements were subject to a review by the auditors and the review report is attached as part of the Half Year Report. 11. Attachments Details of attachments (if any): The Half Year Report of Amplia Therapeutics Limited for the half-year ended 30 September 2025 is attached. 12. Signed Signed ___________________________ Date: 27 November 2025 Warwick Tong Non-Executive Chairman Amplia Therapeutics Ltd HALF-YEAR REPORT 30 September 2025 1 F I G H T C Amplia Therapeutics Limited Corporate directory 30 September 2025 1 Directors Dr. Warwick Tong (Non-Executive Chairman) Dr. Robert Peach (Non-Executive Director) Dr. Christopher Burns (CEO and Managing Director) Ms. Jane Bell AM (Non-Executive Director) Company secretary Mr. Andrew J. Cooke Registered office Level 5, 90 William Street Melbourne VIC 3000 Australia Share register Computershare Investor Services Pty Limited Level 3, 60 Carrington Street Sydney NSW 2000 Australia Telephone: 1300 556 161 (within Australia) + 61 3 9415 4000 (outside Australia) Website: www.investorcentre.com/contact Auditor Grant Thornton Audit Pty Ltd Australia Stock exchange listing Amplia Therapeutics Limited shares are listed on the Australian Securities Exchange (ASX code: ATX) Website www.ampliatx.com Amplia Therapeutics Limited Contents 30 September 2025 2 Directors' report 3 Auditor's independence declaration 8 Consolidated statement of profit or loss and other comprehensive income 9 Consolidated statement of financial position 10 Consolidated statement of changes in equity 11 Consolidated statement of cash flows 12 Notes to the consolidated financial statements 13 Directors' declaration 19 Independent auditor's review report to the members of Amplia Therapeutics Limited 20 Amplia Therapeutics Limited Directors' report 30 September 2025 3 The Directors present their report, together with the financial statements, on the consolidated entity (referred to hereafter as the 'Group') consisting of Amplia Therapeutics Limited (referred to hereafter as the 'Company' or 'parent entity') and the entities it controlled at the end of, or during, the half-year ended 30 September 2025. Directors The names of the Directors in office at any time during or since the period are: Name and independence status Period of office and special responsibilities Warwick Tong Independent Non-Executive Director and Chair Appointed as Non-Executive Director on 4 May 2018 and Chair since 25 May 2018. Member of the Audit & Risk Committee and the Remuneration Committee. Robert Peach Independent Non-Executive Director Appointed as Non-Executive Director on 2 September 2015 and is Chair of the Remuneration Committee and a member of the Audit & Risk Committee. Jane Bell Independent Non-Executive Director Appointed as Non-Executive Director on 12 April 2021 and is also Chair of the Audit & Risk Committee and a member of the Remuneration Committee. Christopher Burns CEO and Managing Director Appointed as Non-Executive Director on 4 May 2018. Appointed Chief Executive Officer and Managing Director starting 5 December 2022. Principal activities The principal activity of the Company is development of its Focal Adhesion Kinase (FAK) inhibiting drug candidates Narmafotinib (AMP945) and AMP886. These assets represent highly attractive compounds for clinical development possessing excellent potency and selectivity in biological assay systems; good pharmacokinetics, bioavailability and drug-like properties; promising efficacy in a range of preclinical studies; and, appropriate chemical properties for manufacturing scale- up and long-term stability. The Company is focused on the development of these drug candidates for potential use in multiple indications in oncology (e.g. pancreatic cancer) and chronic fibrotic diseases. Financial update The loss for the Group after providing for income tax for the half-year period ended 30 September 2025 amounted to $4,176,563 (30 September 2024: $2,814,163). Total current assets at the beginning of the period amounted to $14,928,778 which cash and cash equivalents totalled $10,863,278. At 30 September 2025, total current assets had increased to $36,093,466. Of this amount, $29,156,461 was represented by cash and cash equivalents and $6,402,279 was represented by the R&D tax incentive receivable. Total liabilities at the beginning of the period amounted to $1,912,157. This decreased to $1,612,127 at the end of the period. Review of operations The focus for the Company over the reporting period has been on progressing the clinical studies of our lead asset narmafotinib in advanced pancreatic cancer. The ACCENT clinical trial, where the combination of narmafotinib with the chemotherapies gemcitabine and Abraxane® is being investigated, is the further advanced study. A total of 55 patients have been recruited into the Phase 2a stage of the study at sites in Australia and Korea. A second clinical trial, where the combination of narmafotinib with the chemotherapy FOLFIRINOX is being explored, has recently begun. Promising clinical data from an interim analysis of the ACCENT study was disclosed publicly over the reporting period. In June it was announced that one patient achieved a complete response, while another showed a pathological complete response after surgery revealed the remaining lesions were non-malignant. Importantly, an interim assessment of the primary clinical endpoint – the objective response rate (ORR) – was reported in September as 33%, notably superior to 23% recorded for chemotherapy alone. The ORR is a globally acknowledged metric of clinical efficacy in oncology trials and represents the percentage of patients who achieve a clinical response (complete or partial) that is sustained for >2 months. In addition to the promising efficacy readouts, an interim measure of Progression Free Survival of 7.6 months was also reported. This represents a two-month improvement over the reported data for chemotherapy alone. A two-month improvement in PFS for patients with advanced pancreatic cancer, a highly aggressive cancer, is considered a meaningful improvement in response. Amplia Therapeutics Limited Directors' report 30 September 2025 4 Also noteworthy is that the interim data analysis indicated that narmafotinib is generally well tolerated by patients and does not appear to worsen the side-effects of chemotherapy. The Company also made progress in initiating the second clinical trial of narmafotinib over this half year. Thus, over June and July, the Company announced that first US, and then Australian ethics approval for the trial had been obtained. The two Australian trial sites opened in late August and the first patient in the trial began the study in September. The trial branding as the AMPLICITY trial was announced and a website for potential patients and other interested parties was also launched. In September the Company announced that the US Patent and Trademark Office had informed the Company of the allowance of a key patent. The patent describes the specific chemical form of narmafotinib currently employed in the clinical trials, and follows on from previous notification of grant from the European and Japanese Patent Offices. It was also announced that this same patent had been granted in Australia, India, Korea, Singapore, and New Zealand. In September the Company reported that the United States Adopted Names (USAN) Council had formally adopted the drug name narmafotinib representing an important step in the drug’s development in the United States. On 23 July 2025, the Company announced a A$27.6 million capital raise to fund clinical and other planned activities into 2027. This included a $25.1 million institutional placement and a $2.5 million Share Purchase Plan, both well supported by investors in Australia and overseas. Material Business Risks The current and future performance of the Company may be affected by changing circumstances, uncertainties, and risks specific to the Company and the Company’s business activities, as well as general risks. (a) Clinical development risk The nature of clinical drug development has inherent risks, with many drug candidates entering clinical trial failing to be successfully developed into marketable products. The Company is currently undertaking a clinical trial with its lead drug narmafotinib in advanced pancreatic cancer patients. Clinical trials have many associated risks which may impact commercial potential and therefore future profitability. Such trials may fail to recruit patients at a sufficient rate, and a slower than expected recruitment will mean slower than expected data points so a longer period incurring overheads and personnel costs. Clinical trialling may reveal drug candidates to be unsafe or poorly tolerated in the patient population being tested. The drugs may also be shown to be only modestly effective, thereby limiting commercial potential, or ineffective. Any of these outcomes will likely have a significant adverse effect on the Company, the value of its securities and the future commercial development of its drug candidates, including narmafotinib. Clinical trials might also potentially expose the Company to product liability claims in the event its products in development have unexpected effects on clinical subjects. (b) Regulatory approvals The Company may be unable to secure and maintain necessary approvals from regulatory agencies and institutional bodies (clinics and hospitals) to conduct its clinical trials. Using funds raised in the Offer, the Company plans to initiate a Phase 2 clinical trial (as an Investigator Initiated Trial) in advanced ovarian cancer patients. There is no assurance that regulatory bodies and local ethics committees will approve the Company’s plans to recruit these patients. (c) Regulatory and reimbursement approvals The research, development, manufacture, marketing and sale of products developed by the Company are subject to varying degrees of regulation by a number of government authorities in Australia and overseas. Pharmaceutical products under development, such as drug candidate narmafotinib, must undergo a comprehensive and highly regulated development and review process before receiving approval for marketing. The process includes the provision of clinical data relating to the quality, safety and efficacy of the products for their proposed use. There is no guarantee that such regulatory approvals will be granted. (d) Chemistry, manufacturing and controls The ACCENT clinical trial currently underway requires supply of narmafotinib drug product (capsules). There are risks in the shipment, storage and handling of drug product that may render the material unavailable or inappropriate for clinical usage. For clinical trial sites in South Korea, supplies of the chemotherapies gemcitabine and Abraxane are also required. There are risks in the supply, shipment, storage and handling of drug product that may render the material unavailable or inappropriate for clinical usage. Amplia Therapeutics Limited Directors' report 30 September 2025 5 (e) Commercialisation of products and potential market failure The Company has not yet commercialised any products and as yet has no revenues. The Company is also dependent on commercially attractive markets remaining available to it during the commercialisation phase and there is a risk that, once developed and ready for sale, commercial sales may not be achieved. Furthermore, any products developed by the Company may prove to be uneconomical to market or compete with alternative products marketed by third parties, or not be as attractive or efficacious as alternative treatments. (f) Competition The biotechnology and pharmaceutical industries are intensely competitive and subject to rapid and significant change. A number of companies, both in Australia and abroad, may be pursuing the development of products that target the same markets and/or diseases that the Company is targeting. The Company’s products may compete with existing products that are already available to customers. The Company may face competition from parties who have substantially greater resources than the Company. Competing products may be superior to the Company’s products, which would adversely impact the commercial viability of the Company’s products. (g) Dependence upon key personnel The Company’s ability to attract and retain personnel will have a direct impact on its ability to deliver its project commitments. The Company depends on the talent and experience of its personnel as an important asset. There may be a negative impact on the Company if any of its key personnel leave. It may be difficult to replace them, or to do so in a timely manner or at comparable expense. Additionally, any key personnel of the Company who leave to work for a competitor may adversely impact the Company. Additionally, increases in recruitment fees, wages and contractor costs may adversely impact upon the financial performance of the Company. (h) Research & Development (R&D) Tax Incentive Rebates The Company is currently entitled to receive an R&D rebate on part of its expenditure in research and development. There is a risk that the Australian Government may make material changes to the rebate scheme, which may adversely impact the funding available to the Company to fund its operations. In order to obtain an R&D rebate on that part of its expenditure that is incurred out of Australia the Company must first gain approval for that expenditure from the Australian Government. Such an approval is called an Advanced Finding. The Company has received Advanced Findings for R&D work which is planned for its lead assets narmafotinib and AMP886. (i) Growth There is a risk that the Company may be unable to manage its future growth successfully. The ability to hire and retain skilled personnel as outlined above may be a significant obstacle to growth. (j) Commercial partners The Company’s growth strategy may be impacted if it is unable to find suitable commercialisation partners. The Company's due diligence processes may not be successful and a commercial partnership may not perform to the level expected. (k) Intellectual Property The Company’s ability to commercialise any product depends upon its ability to protect its intellectual property and any improvements to it. The intellectual property may not be capable of being legally protected, it may be the subject of unauthorised disclosure or be unlawfully infringed, or the Company may incur substantial costs in asserting or defending its intellectual property rights. (l) Revenues and Profitability The Company does not currently generate revenue from product sales nor are revenues anticipated in the short to medium term. The Company’s ability to achieve both revenues and profitability is dependent on a number of factors, including its ability to complete successful clinical trials, obtain regulatory approval for its products and successfully commercialise those products. There is no guarantee that the Company’s products (including the drug narmafotinib) will be commercially successful. (m) Economic General economic conditions, movements in financial markets, interest and inflation rates and currency exchange rates may have an adverse effect on the Company's business and production activities, as well as on its ability to fund those activities. Amplia Therapeutics Limited Directors' report 30 September 2025 6 (n) Market Conditions Share market conditions may affect the value of the Company's quoted shares (and options to acquire quoted shares) regardless of the Company's operating performance. Share market conditions are affected by many factors such as: (a) general economic outlook; (b) introduction of tax reform or other new legislation; (c) interest rates and inflation rates; (d) changes in investor sentiment toward particular market sectors; (e) the demand for, and supply of, capital; and (f) terrorism or other hostilities. The market price of securities can fall as well as rise and may be subject to varied and unpredictable influences on the market for equities in general and pharmaceutical stocks in particular. Neither the Company nor the Directors warrant the future performance of the Company or any return on an investment in the Company. (o) Litigation There is a risk that the Company may in future be the subject of or required to commence litigation. There is, however, no litigation, mediation, conciliation or administrative proceeding taking place, pending or threatened against the Company. (p) Tax risks Changes to the rate of taxes imposed on the Company (including in overseas jurisdictions in which the Company operates now or in the future) or tax legislation generally may affect the Company and its shareholders. In addition, an interpretation of Australian tax laws by the Australian Taxation Office that differs to the Company’s interpretation may lead to an increase in the Company’s tax liabilities and a reduction in shareholder returns. Personal tax liabilities are the responsibility of each individual investor. The Company is not responsible either for tax or tax penalties incurred by investors. (q) Additional capital requirements The Company's capital requirements depend on numerous factors. The Company may require further financing in addition to amounts raised under the capital raising. Any additional equity financing will dilute shareholdings, and debt financing, if available, may involve restrictions on financing and operating activities. If the Company is unable to obtain additional financing as needed, it may be required to reduce the scope of its operations, its production levels, or scale back its research and development and/or clinical trials as the case may be. There is no guarantee that the Company will be able to secure any additional funding or be able to secure funding on terms favourable to the Company. Significant changes in the state of affairs During the period the Company completed the following equity issues: ● On 4 July 2025, the Company issued 720,000 ordinary shares at $0.14 per share upon conversion of options. ● On 23 July 2025, the Company issued 1,000,000 ordinary shares at $0.14 per share upon conversion of options. ● On 29 July 2025, the Company issued 96,804,354 shares at $0.23 per share in relation to Tranche 1 of the placement capital raise. ● On 29 August 2025, the Company issued 14,703,299 shares at $0.18 per share in relation to a share purchase plan. ● On 1 September 2025, the Company issued 11,891,307 shares at $0.23 per share in relation to Tranche 2 of the placement capital raise. There were no other significant changes in the state of affairs of the Company during the financial half-year. Matters subsequent to the end of the financial half-year On 8 October 2025, 5,626,000 unlisted options with exercise price of $0.2533 expired. On 28 October 2025, the Company received R&D refund of $3.77m relating to the year ended 31 March 2025. No other matter or circumstance has arisen since 30 September 2025 that has significantly affected, or may significantly affect the Group's operations, the results of those operations, or the Group's state of affairs in future financial years. Auditor's independence declaration A copy of the auditor's independence declaration as required under section 307C of the Corporations Act 2001 is set out immediately after this Directors' report. Amplia Therapeutics Limited Directors' report 30 September 2025 7 This report is made in accordance with a resolution of Directors, pursuant to section 306(3)(a) of the Corporations Act 2001. On behalf of the Directors ___________________________ Warwick Tong Non-Executive Chairman 27 November 2025 Grant Thornton Audit Pty Ltd Level 22 Tower 5 Collins Square 727 Collins Street Melbourne VIC 3008 GPO Box 4736 Melbourne VIC 3001 T +61 3 8320 2222 www.grantthornton.com.au ACN-130 913 594 Grant Thornton Audit Pty Ltd ACN 130 913 594 a subsidiary or related entity of Grant Thornton Australia Limited ABN 41 127 556 389 ACN 127 556 389. ‘Grant Thornton’ refers to the brand under which the Grant Thornton member firms provide assurance, tax and advisory services to their clients and/or refers to one or more member firms, as the context requires. Grant Thornton Australia Limited is a member firm of Grant Thornton International Ltd (GTIL). GTIL and the member firms are not a worldwide partnership. GTIL and each member firm is a separate legal entity. Services are delivered by the member firms. GTIL does not provide services to clients. GTIL and its member firms are not agents of, and do not obligate one another and are not liable for one another’s acts or omissions. In the Australian context only, the use of the term ‘Grant Thornton’ may refer to Grant Thornton Australia Limited ABN 41 127 556 389 ACN 127 556 389 and its Australian subsidiaries and related entities. Liability limited by a scheme approved under Professional Standards Legislation. Auditor’s Independence Declaration To the Directors of Amplia Therapeutics Limited In accordance with the requirements of section 307C of the Corporations Act 2001, as lead auditor for the review of Amplia Therapeutics Limited for the half-year ended 30 September 2025, I declare that, to the best of my knowledge and belief, there have been: a no contraventions of the auditor independence requirements of the Corporations Act 2001 in relation to the review; and b no contraventions of any applicable code of professional conduct in relation to the review. Grant Thornton Audit Pty Ltd Chartered Accountants J D Vasiliou Partner – Audit & Assurance Melbourne, 27 November 2025 8 Amplia Therapeutics Limited Consolidated statement of profit or loss and other comprehensive income For the half-year ended 30 September 2025 Note 30 September 2025 30 September 2024 $ $ The above consolidated statement of profit or loss and other comprehensive income should be read in conjunction with the accompanying notes 9 Revenue and other income R&D tax incentive 5 2,630,572 1,394,916 Government grants - 12,000 Interest income 204,525 84,620 Total revenue and other income 2,835,097 1,491,536 Expenses Research & development expenses (4,999,152) (2,800,243) Administrative & general expenses (1,759,950) (1,269,110) Share based compensation (53,575) (66,736) Patent & associated expenses (158,082) (71,023) Depreciation and amortisation expense (36,297) (43,361) Total expenses (7,007,056) (4,250,473) Operating loss (4,171,959) (2,758,937) Interest expense (4,604) (55,226) Loss before income tax expense (4,176,563) (2,814,163) Income tax expense - - Loss after income tax expense for the half-year attributable to the owners of Amplia Therapeutics Limited (4,176,563) (2,814,163) Other comprehensive income for the half-year, net of tax - - Total comprehensive loss for the half-year attributable to the owners of Amplia Therapeutics Limited (4,176,563) (2,814,163) Cents Cents Basic and diluted earnings per share 11 (0.98) (1.11) Amplia Therapeutics Limited Consolidated statement of financial position As at 30 September 2025 Note 30 September 2025 31 March 2025 $ $ The above consolidated statement of financial position should be read in conjunction with the accompanying notes 10 Assets Current assets Cash and cash equivalents 29,156,461 10,863,278 R&D tax incentive receivable 6 6,402,279 3,771,707 Prepayments 130,319 108,963 Other assets 404,407 184,830 Total current assets 36,093,466 14,928,778 Non-current assets Property, plant and equipment 23,551 4,752 Right-of-use assets 378,279 12,612 Intangibles 7 7,937,932 7,937,932 Other assets 106,992 53,033 Total non-current assets 8,446,754 8,008,329 Total assets 44,540,220 22,937,107 Liabilities Current liabilities Accounts payable & accrued liabilities 1,116,416 1,804,046 Lease liabilities 83,836 13,893 Provisions 80,906 70,118 Total current liabilities 1,281,158 1,888,057 Non-current liabilities Lease liabilities 297,581 - Provisions 33,388 24,100 Total non-current liabilities 330,969 24,100 Total liabilities 1,612,127 1,912,157 Net assets 42,928,093 21,024,950 Equity Issued capital 8 193,430,477 167,389,241 Reserves 9 (1,027,041) (826,193) Accumulated losses (149,475,343) (145,538,098) Total equity 42,928,093 21,024,950 The above consolidated statement of changes in equity should be read in conjunction with the accompanying notes 11 Total equity Issued capital Share option reserve Other reserves Accumulated losses $ $ $ $ $ 151,529,215 722,078 (1,818,617) (139,014,367) 11,418,309 - - - (2,814,163) (2,814,163) - - - - - - - - (2,814,163) (2,814,163) - 16,736 - - 16,736 4,467,441 - - - 4,467,441 (368,579) 53,708 - - (314,871) - (48,299) - 48,299 - 155,628,077 744,223 (